Financings In Brief
This article was originally published in The Gray Sheet
Executive Summary
Amedica cancels IPO plan: Orthopedic implant maker Amedica cancels plans for an initial public offering, citing adverse stock market conditions in an Aug. 1 statement. The firm says its cash position is "adequate" to continue preparations for a 2008 U.S. market debut of its initial Valeo silicon nitride ceramic spinal implant, and that it will pursue additional financing at an "appropriate" time in the future (1"The Gray Sheet" June 4, 2007, p. 7)...
You may also be interested in...
Natus Medical Buys Alpine Biomed To Expand Neurodiagnostics Portfolio
Natus Medical will expand its global presence in the neurology market through its $43.2 million acquisition of neurological disorder diagnostic equipment maker Alpine Biomed, announced Sept. 14
Natus Medical Buys Alpine Biomed To Expand Neurodiagnostics Portfolio
Natus Medical will expand its global presence in the neurology market through its $43.2 million acquisition of neurological disorder diagnostic equipment maker Alpine Biomed, announced Sept. 14
People In Brief
Alpine Biomed Appoints CEO: John Arnott takes the top spot at the gastroenterology and neurology diagnostic product firm Aug. 14. Arnott has more than 20 years experience in global healthcare organizations, including leadership positions at Hospira, Abbott Laboratories, Wellcome Diagnostics and the National Health Service in the United Kingdom. Alpine's gastro products diagnose gastroesophageal reflux disease while the neuro products are for conditions such as carpal tunnel syndrome and sleep disorders. The Fountain Valley, Calif. company recently purchased certain neuropathy diagnostics from Medtronic (1"The Gray Sheet" Aug. 6, 2007, p. 13)...